News stories about Aimmune Therapeutics (NASDAQ:AIMT) have been trending somewhat positive this week, according to Accern. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aimmune Therapeutics earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 46.5923354072562 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:

Aimmune Therapeutics (NASDAQ:AIMT) opened at 23.17 on Tuesday. The stock’s 50 day moving average price is $20.69 and its 200-day moving average price is $20.22. Aimmune Therapeutics has a 1-year low of $14.11 and a 1-year high of $27.31. The company’s market cap is $1.17 billion.

Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.65) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by $0.01. On average, analysts forecast that Aimmune Therapeutics will post ($2.71) earnings per share for the current year.

A number of research firms have recently commented on AIMT. Zacks Investment Research cut Aimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. Piper Jaffray Companies set a $38.00 target price on Aimmune Therapeutics and gave the company a “buy” rating in a research note on Thursday, July 27th. ValuEngine cut Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 27th. Wedbush reaffirmed an “ourperform” rating and set a $42.00 target price on shares of Aimmune Therapeutics in a research note on Monday, August 14th. Finally, BidaskClub cut Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. Aimmune Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $32.50.

TRADEMARK VIOLATION NOTICE: “Aimmune Therapeutics (AIMT) Receiving Somewhat Favorable Press Coverage, Study Shows” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at https://www.thecerbatgem.com/2017/09/12/aimmune-therapeutics-aimt-receiving-somewhat-favorable-press-coverage-study-shows.html.

In other news, insider Susan E. Barrowcliffe sold 15,000 shares of Aimmune Therapeutics stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $20.26, for a total transaction of $303,900.00. Following the sale, the insider now owns 15,000 shares of the company’s stock, valued at approximately $303,900. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Stephen George Dilly sold 49,400 shares of Aimmune Therapeutics stock in a transaction that occurred on Friday, June 23rd. The shares were sold at an average price of $20.21, for a total transaction of $998,374.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 236,860 shares of company stock worth $5,021,672. Corporate insiders own 24.56% of the company’s stock.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Insider Buying and Selling by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Stock Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related stocks with our FREE daily email newsletter.